Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 11Thoracic 10Tumor-Agnostic 9Lymphoid 5Dermatologic 5Breast 5Genitourinary 3CNS 3Gastrointestinal 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 139Lenalidomide 75Cyclophosphamide 73Bortezomib 73Calcium Dobesilate 57fludarabine 49pomalidomide 43daratumumab 39fludarabine phosphate 34carfilzomib 33Melphalan 29dexamethasone acetate 24dexamethasone 21-phosphate 24auricularum 22Filgrastim 18Whole-Body Irradiation 15Biopsy 14ixazomib 13isatuximab 13Magnetic Resonance Spectroscopy 13Granulocyte Colony-Stimulating Factor 13Vorinostat 12Tacrolimus 12Specimen Handling 12Sirolimus 12Peripheral Blood Stem Cell Transplantation 12venetoclax 11belantamab mafodotin 11Rituximab 11Panobinostat 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Midazolam × Plasma cell × Clear all
NCT01456689 2020-12-17

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Novartis

Phase 1 Completed
79 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡